MichaelDKaufmanMD

PubMed

• 22 citations
  Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
  Bryan D. Smith, Michael Kaufman, Scott C. Wise, Yu Mi Ahn, Timothy M. Caldwell, Cynthia B. Leary, Wei-Ping Lu, Gege Tan, Lakshminarayana Vogeti, Subha Vogeti, Breelyn ...> ;Molecular Cancer Therapeutics. 2021 Sep 2
• 45 citations
  A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
  Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. W...> ;Molecular Cancer Therapeutics. 2020 Feb 1
• 151 citations
  Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
  Bryan D. Smith, Michael Kaufman, Wei Ping Lu, Anu Gupta, Cynthia B. Leary, Scott C. Wise, Thomas J. Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L. Bulfer, Timothy M. Cald...> ;Cancer Cell. 2019 May 13
• 82 citations
  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.
  Allison S. Harney, George S. Karagiannis, Jeanine Pignatelli, Bryan D. Smith, Ece Kadioglu, Scott C. Wise, Molly M. Hood, Michael Kaufman, Cynthia B. Leary, Wei Ping L...> ;Molecular Cancer Therapeutics. 2017 Nov 1
• 212 citations
  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
  Sheng-Bin Peng, Henry James Robert, Michael Kaufman, Wei-Ping Lu, Bryan D. Smith, Subha Vogeti, Thomas J. Rutkoski, Scott C. Wise, Lawrence Chun, Youyan Zhang, Robert ...> ;Cancer Cell. 2015 Sep 14
• 53 citations
  Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
  Bryan D. Smith, Michael Kaufman, Cynthia B. Leary, Benjamin A. Turner, Scott C. Wise, Yu Mi Ahn, R. John Booth, Timothy M. Caldwell, Carol L. Ensinger, Molly M. Hood, ...> ;Molecular Cancer Therapeutics. 2015 Aug 18
• 69 citations
  Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with mini...
  Henry James Robert, Michael Kaufman, Sheng-Bin Peng, Yu Mi Ahn, Timothy M. Caldwell, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Wei-Ping Lu, Molly M. Hood, Thomas ...> ;Journal of Medicinal Chemistry. 2015 May 12
• 19 citations
  Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
  Michael Kaufman, Bruce A.C. Cree, Jérôme De Seze, Robert J. Fox, Ralf Gold, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Xavier Montalban, Bianca Weinstock-Gutt...> ;Journal of Neurology. 2015 Feb 1
• 53 citations
  Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment
  Youngjoo Kwon, Bryan D. Smith, Yan Zhou, Michael Kaufman, Andrew K. Godwin> ;Oncogene. 2015 Jan 8
• MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
  Fox RJ, Cree BAC, De Sèze J, Gold R, Hartung H, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P> ;Neurology. 2014-04-29
• 58 citations
  Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
  Michael Kaufman, Gabriel Pardo, Howard Rossman, Marianne T. Sweetser, Fiona Forrestal, Petra Duda> ;Journal of the Neurological Sciences. 2014 Jun 15
• 18 citations
  HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis.
  Suhayl Dhib-Jalbut, Reuben M. Valenzuela, Kouichi Ito, Michael Kaufman, Mary Ann Picone, Steve Buyske> ;Multiple Sclerosis and Related Disorders. 2013 Oct 1
• 10 citations
  Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase
  Noel A. Powell, Jennifer K. Hoffman, Fred L. Ciske, Michael Kaufman, Jeffrey T. Kohrt, John Quin, Derek James Sheehan, Amy M. Delaney, Sangita M. Baxi, Cornel Catana, ...> ;Bioorganic & Medicinal Chemistry Letters. 2013 Feb 15
• 30 citations
  Novel and selective spiroindoline-based inhibitors of Sky kinase.
  Noel A. Powell, Jeffrey T. Kohrt, Kevin J. Filipski, Michael Kaufman, Derek James Sheehan, Jeremy E. Edmunds, Amy M. Delaney, Yuli Wang, Francis Bourbonais, Doh-Yeel L...> ;Bioorganic & Medicinal Chemistry Letters. 2012 Jan 1
• 147 citations
  Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
  Wayne W. Chan, Scott C. Wise, Michael Kaufman, Yu Mi Ahn, Carol L. Ensinger, Torsten Haack, Molly M. Hood, Jennifer L. Jones, John Lord, Wei Ping Lu, David Miller, Pat...> ;Cancer Cell. 2011 Apr 12
• 28 citations
  Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.
  Michael Kaufman, R Lee, H. J. Norton> ;Multiple Sclerosis. 2011 Apr 1
• 21 citations
  Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region
  Yu Mi Ahn, Michael Clare, Carol L. Ensinger, Molly M. Hood, John Lord, Wei-Ping Lu, David F. Miller, Patt William Chester, Bryan D. Smith, Lakshminarayana Vogeti, Mich...> ;Bioorganic & Medicinal Chemistry Letters. 2010 Oct 1
• 229 citations
  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
  Daniel Wynn, Michael Kaufman, Xavier Montalban, Timothy Vollmer, Jack H. Simon, Jacob Elkins, Gilmore O'neill, Lauri Neyer, James Sheridan, Chungchi Wang, Alice Fong, ...> ;The Lancet. Neurology. 2010 Apr 1
• Double-lumen tubes: which lumen for the gum elastic bougie?
  Michael S. Stix, Sana Ata, Marten Wolckenhaar, Michael Kaufman> ;Anesthesia and Analgesia. 2010 Jan 1
• 44 citations
  Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004-2007.
  Roman Schumann, Stephanie B. Jones, Bronwyn Cooper, Scott D. Kelley, Mark Vanden Bosch, Vilma E. Ortiz, Kathleen A. Connor, Michael Kaufman, Alan M. Harvey, Daniel B. ...> ;Obesity. 2009 May 1
• 207 citations
  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
  Stephen Douglas Barrett, Alexander James Bridges, David T. Dudley, Alan R. Saltiel, James H. Fergus, Cathlin Marie Flamme, Amy M. Delaney, Michael Kaufman, Sophie LePa...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Dec 15
• 41 citations
  2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (...
  Joseph S. Warmus, Cathlin Marie Flamme, Lu Yan Zhang, Stephen Douglas Barrett, Alexander James Bridges, Huifen Chen, Richard Gowan, Michael Kaufman, Judy Sebolt-Leopol...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Dec 1
• 15 citations
  Patient perceptions of multiple sclerosis-related care: Comparisons by practice specialty of principal care physician
  Robert J. Buchanan, Michael Kaufman, Li Zhu, Wesley James> ;Neurorehabilitation. 2008 Jan 1
• 31 citations
  4-Anilino-5-carboxamido-2-pyridone Derivatives as Noncompetitive Inhibitors of Mitogen-Activated Protein Kinase Kinase
  Julie Ann Spicer, Gordon W. Rewcastle, Michael Kaufman, Shannon Leigh Black, Mark Stephen Plummer, William A. Denny, John Quin, Aurash B. Shahripour, Stephen Douglas B...> ;Journal of Medicinal Chemistry. 2007 Sep 19
• 32 citations
  Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.
  Ronald W. Sarver, Jeanette Peevers, Wayne L. Cody, Fred L. Ciske, Jim Dyer, S. Donald Emerson, Jeanne C. Hagadorn, Daniel D. Holsworth, Mehran Jalaie, Michael Kaufman,...> ;Analytical Biochemistry. 2007 Jan 1
• Join now to see all

Journal Articles

• MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study  
  Fox RJ, Cree BA, De Seze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P, Neurology, 1/1/2014
• HLA DR and DQ predict response to glatiramer acetate in multiple sclerosis  
  Dhib-Jalbut S, Valenzuela RM, Ito K, Kaufman M, Picone M, Buyske S, Mult Scler Rel Dis, 1/1/2013
• Course of relapsing-remitting MS before, during, and after natalizumab  
  Kaufman MD, Lee R, Norton HJ, Multiple Sclerosis J, 1/1/2011
• Health-related quality of life among young adults with multiple sclerosis  
  Buchanan RJ, Huang CF, Kaufman M, Int J MS Care, 1/1/2010
• Mitoxantrone in the treatment of multiple sclerosis in African Americans compared to Caucasians with secondary progressive multiple sclerosis  
  Moore L, Kaufman M, Conway J, Int J MS Care, 1/1/2010
• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta  
  Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O’Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, for the CHOICE investigators, Lancet Neurol, 1/1/2010
• Relationships between information processing, depression, fatigue and cognition in multiple sclerosis  
  Diamond BJ, Johnson SK, Kaufman M, Graves L, Arch Clin Neurppsychol, 1/1/2008
• Neurologists versus non-neurologists Care of multiple sclerosis patients  
  Buchanan RJ, Kaufman M, Zhu L, James W, Int J MS Care, 1/1/2008
• Patient perceptions of multiple sclerosis-related care: Comparisons by practice specialty of principal care physician  
  Buchanan RJ, Kaufman M, Zhu L, James W, NeuroRehabilitation, 1/1/2008
• Examining the effects of stressors and resources on multiple sclerosis among African Americans and Whites  
  Johnson SK, Terrell T, Sargent C, Kaufman M, Stress and Health, 1/22/2007
• Coping with MS: How to give patients their lives back  
  Kaufman, M, Practical Neurology, 1/1/2007
• Adherence to therapy: using an evidence-based protocol  
  Moore LA, Kaufman MD, Algozzine R, Irish N, Martin M, Posey CR, Rehabilitation Nursing, 1/1/2007
• The effect of gingko biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial  
  Johnson, S.K., Diamond, B.J., Rausch, S., Kaufman, M., Schiflett, S., & Graves, L, EXPLORE: The Journal of Science and Healing, 1/1/2006
• Juvenile Metachromatic Leurkodystrophy Mimicking Relapsing-Remitting Multiple Sclerosis  
  Kaufman M, Parrott JH, Int J MS Care, 1/1/2006
• Longitudinal assessment of multiple sclerosis patients and reimbursement issues  
  Kaufman M, Cutter G, Schwid S, Johnson K, Halper J, Birnhaum G, et al, Int J MS Care, 1/1/2005
• Perspective from Practice  
  Kaufman MD, Neura, Quarterly Column, 1/1/2005
• Multiple Sclerosis: Severity and Progression Rate in African Americans Compared with Whites  
  Kaufman MD, Moyer D, Bivens J, Johnson S, Am J Phys Med Rehabil, 1/1/2003
• Book review: Herndon RM Multiple Sclerosis: Immunology, Pathology, and Pathophysiology Demos Medical Publishing, Inc, New York, 2003  
  Kaufman MD, Int. J. MSCare, 1/1/2003
• Combining Therapies with IFN beta for Relapsing and Early Progressive MS: A Review  
  Kaufman M, Int J MSCare, 1/1/2002
• A Randomized Controlled Safety Trial of Interferon beta-1a and Oral Cyclophosphamide in MS  
  Kaufman M, Norton HJ, Sonnenfeld G, Int J MSCare, 1/1/2002
• Is C pneumoniae Found in Spinal Fluid Samples from MS Patients? Conflicting Results  
  Kaufman MD, Gaydos C, Sriram S, Boman J, Tondella ML, Norton HJ, Multiple Sclerosis, 1/1/2002
• Ishihara's tests for color blindness: a useful indicator of visual involvement in multiple sclerosis  
  Kaufman MD, Lutz DM, Norton J, Int J MSCare, 1/1/2000
• Multiple Sclerosis: Diagnosis, medical management and rehabilitation Demos, New York, 2000  
  Kaufman MD, Int. J. MSCare, 1/1/2000
• The significant change for the Timed 25-foot Walk in the Multiple Sclerosis Functional Composite  
  Kaufman MD, Moyer D, Norton J, Multiple Sclerosis, 1/1/2000
• A controlled investigation of bodywork in multiple sclerosis  
  Johnson S, Fredericks J, Kaufman MD, J Alternative & Complementary Medicine, 1/1/1999
• Join now to see all

Books/Book Chapters

• Medlink (on-line text of neurology). 
  Chapter: Balo Concentric Sclerosis. 
  Kaufman MDEditors: Sid Gilman.2009
• Medlink (on-line text of neurology). 
  Chapter: Treatment of Multiple Sclerosis Symptoms. 
  Kaufman MDEditors: Richard Johnson.2002
• Proceedings. Fourth Meeting of the European Society for Chlamydia research, Helsinki, Finland. 
  Chapter: Lack of detection of Chlamydia Pneumoniae by PCR and tissue culture in cerebrospinal fluid from multiple sclerosis patients and controls. 
  Theodore M, Kaufman M, Wagar E, Myers L, Quinn TC, Gaydos CAEditors: Pekka Saikku.Societa Editrice Esculapio, Bologna, Italy2000
• HSSA-Editorial, Neurology Board Review, Education Division 
  Chapter: Multiple Sclerosis. 
  Kaufman MDEditors: American Academy of Family Physicians.1999
• Saunders Manual of Medical Practice 
  Chapter: Multiple Sclerosis. 
  Page 1058 - 1060Kaufman MDEditors: Rakel RE.Saunders Co, Philadelphia, PA1996
• Encyclopedia of Clinical Neuropsychology. 
  Chapter: Neuropathy 
  Kaufman MDEditors: Kreutzer JS, DeLuca J, Caplan B.Springer, Heidelberg, Germany
• Join now to see all

Abstracts/Posters

• Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNbeta-1a in RRMS patients. Poster
  Douglas L Arnold, Ludwig Kappos, Eva Havrdova, Krzysztof Selmaj, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Katherine Rie..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
• Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis.
  Krzysztof Selmaj, Ludwig Kappos, Douglas L. Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Katherine Ri..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
• Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of Daclizumab HYP vs. Interferon beta-1a in RRMS patients.
  Ludwig Kappos, Krzysztof Selmaj, Douglas Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Eren Demirhan, Marianne Sweets..., Joint ACTRIM-ECTRIMS meeting, Boston, MA, 1/10/2014
• The Joint Commission TJC/Disease-Specific Care (DSC) Certification Programs for Parkinson's Disease (PD)/Multiple Sclerosis (MS)/ Amyotrophic Lateral Sclerosis (ALS) -...
  Conway J, Englert D, Bravver E, Craig C, williams N, Cashdollar S, Price M, Fortier C, Kaufman M, Brooks B, Iyer S, American Academy of Neurology 65th annual meeting, San Diego, CA, 1/1/2013
• Natalizumab Effects During a 6-Month Dose Interruption: Relationship of Pharmacokinetic (PK), Pharmacodynamic (PD), and MRI Measurements.
  Cree, B, De Seze J, Fox R, Gold R, Hartung H-P, Jeffery D, Kappos L, Kaufman M, Montalban X, Weinstock-Guttman B, Woodworth J, Plavina T, Duda P, American Academy of Neurology 65th annual meeting, San Diego, CA, 1/1/2013
• Motor Deficit Evaluated by Timed Functional Measures Correlate with Functional Rating Scale Used in Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), bu...
  Sanjak M, Mays J, Hirsch M, Englert D, Iyer S, Conway J, Kaufman M, Bravver E, Brooks B, American Academy of Neurology 65th annual meeting, San Diego, CA, 1/1/2013
• RESTORE study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity.
  Cree B et al, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Effects of a 24-week natalizumab treatment interruption on quality of life, fatigue, and cognition: results from the RESTORE study.
  Weinstock-Guttman B et. al, American Academy of Neurology Annual Meeting, New Orleans, LA, 1/1/2012
• Observations on the design of secondary progressive MS trials.
  Kaufmann L, Moore M, Kaufman M, Lutz D, Norton J, Cooperative Meeting of the Consortium of MS Centers and the Americas Committee for Treatment and Research in MS, San Diego, CA, 1/1/2012
• Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study.
  Fox R, Kappos L, Cree B, Kaufman M, Jeffery D, Weinstock-Guttman B, Hartung H-P, Gold R, Montalban X, De Seze J, Natarajan A, Morse R, Ticho B, Duda P, ECTRIMS, 1/1/2011
• DECIDE rationale and design: Daclizumab high-yield process monotherapy in RRMS.
  Kappos L, Wiendl H, Kaufman MD, Rose JW, Hardova W, et al, Annual meeting Consortium of MS Centers, San Antonio, TX, 1/1/2010
• Decide rationale/design: daclizumab high yield process monotherapy in relapsing remitting multiple sclerosis (RRMS).
  Kappos L, Wiendl H, Kaufman M, et al, Eur J Neurol, 1/1/2010
• Predictive biomarkers of clinical response to glatiramer acetate (GA) therapy in multiple sclerosis MS. Poster
  Valenzuela RM, Kaufman M, Russo P, Picone M, Halper J, Costello K, Rosaria Y, Ito K, Dhib-Jalbut S, 61st Annual Meeting of the American Academy of Neurology, Seattle, WA, 1/1/2009
• Functional and clinical assessment before and after mitoxantrone.
  Moore LA, Kaufman MD, Edinger A, Consortium of MS Centers Annual Meeting, Denver, CO, 1/28/2008
• A phase 2, randomized, double-blind, placebo-controlled, multicenter study of subcutaneous dacluzumab in patients with active relapsing forms of multiple sclerosis – w...
  K aufman M, Wynn D, Montalban X, Wang M, Fong A, Contemporary Clinical Issues and Case Studies Plenary Session, 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, 1/16/2008
• Perceptions of Multiple Sclerosis Patients Receiving Mitoxantrone Chemotherapy Correlated with Quality of Life Indicators.
  Moore LA, Kaufman M, Edinger A, Sigma Theta Tau International Nursing Honorary Society, 39th Annual Conference, Baltimore, MD, 1/2/2007
• Preliminary CHOICE results: a phase 2, randomized, double-blind, placebo-controlled multicentre study of subcutanieous daclizumab in patients with active, relapsing fo...
  Montalban X, Wynn D, Kaufman M, Wang M, Fong A, ECTRIMS, Prague, Czech Republic, 1/1/2007
• Differential effects of depression and anxiety on measures sensitive to cognitive slowing in multiple sclerosis. Poster
  Johnson, S.K., Holden, J., Diamond, B., Kaufman, M, Archives of Clinical Neuropsychology; 24th Annual Meeting of the National Academy of Neuropsychology, Seattle, WA, 1/1/2004
• New technique to manage betaseron injection site reactions.
  Moore L, Kaufman M, Algozzine R, Rosser C, Irish N, Martin M, MS Trust Sixth Annual Conference, Harrogate, England, 1/1/2002
• The impact of ethnicity, symptom severity, stressors and resources on quality of life in multiple sclerosis.
  Johnson SK, Sargent C, Kaufman M, Society for Behavioral Medicine, 22nd Annual Meeting, Seattle, WA, 1/24/2001
• Safety and tolerabiltiy of the combination of interferon beta-1a and oral cyclophosphamide for patients with multiple sclerosis.
  Kaufman MD, Norton J, Sonnenfeld G, Neurology; 53rd American Academy of Neurology Annual Meeting, Philadelphia, PA, 1/1/2001
• Multiple Sclerosis: Severity and Progression Rate in African Americans Compared with Caucasians.
  Norton HJ, Bivens J, Johnson S, Moyer D, Kaufman MD, Neurology; 53rd American Academy of Neurology Annual Meeting, Philadelphia, PA, 1/1/2001
• Comparison of quantitative sensory testing to the standard clinical examination and self-assessment. Poster
  Kaufman MD, Lutz D, Norton J, Consortium of Multiple Sclerosis Centers, Annual Meeting, Halifax, Nova Scotia, Canada, 1/22/2000
• PCR results for two laboratories for the identification of Chlamydia pneumonia in cerebrospinal fluid of MS patients and controls. Poster
  Kaufman MD, Gaydos C, Sriram S, Ann Neurol; 125th Annual Meeting of the American Neurological Association, Boston, MA, 1/1/2000
• Comparing multiple sclerosis severity in African-Americans and Caucasians. Poster
  Kaufman MD, Johnson SK, Moyer D, Bevins J, Norton J, Eliminating Racial/Ethnic Health Inequalities conference, Charlotte, NC, 1/1/2000
• Join now to see all

Other

• CME article: How to Choose an Immunomodulator in 2010 and Beyond. 
  Kaufman MD
  http://cme.medscape.com/viewprogram/31525
  1/25/2010